Liposomal honokiol, a potent anti-angiogenesis agent, in combination with radiotherapy produces a synergistic antitumor efficacy without increasing toxicity
Open Access
- 1 January 2008
- journal article
- Published by Springer Science and Business Media LLC in Experimental & Molecular Medicine
- Vol. 40 (6), 617-28
- https://doi.org/10.3858/emm.2008.40.6.617
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Enhancement of therapeutic effectiveness by combining liposomal honokiol with cisplatin in ovarian carcinomaInternational Journal of Gynecologic Cancer, 2008
- Inhibition of p53 Response in Tumor Stroma Improves Efficacy of Anticancer Treatment by Increasing Antiangiogenic Effects of Chemotherapy and Radiotherapy in MiceCancer Research, 2006
- Promoter Hypermethylation of Multiple Genes in Sputum Precedes Lung Cancer Incidence in a High-Risk CohortCancer Research, 2006
- Mechanisms of Cell Sensitization to α Radioimmunotherapy by Doxorubicin or Paclitaxel in Multiple Myeloma Cell LinesClinical Cancer Research, 2005
- Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosisBlood, 2005
- Trimodal Cancer Treatment: Beneficial Effects of Combined Antiangiogenesis, Radiation, and ChemotherapyCancer Research, 2005
- NF-κB decoy potentiates the effects of radiation on vascular smooth muscle cells by enhancing apoptosisExperimental & Molecular Medicine, 2005
- A gene therapy for cancer based on the angiogenesis inhibitor, vasostatinGene Therapy, 2002
- The Roadblocks to Angiogenesis BlockersScience, 1998
- Encapsulation of Vincristine in Liposomes Reduces its Toxicity and Improves its Anti-Tumor EfficacyJournal of Liposome Research, 1995